-
SIRT1/2 Inhibitor IV: Practical Research Workflows
2026-09-27
Use SIRT1/2 Inhibitor IV (cambinol) to test how sirtuin activity intersects with lactate signaling, protein modification, and cell phenotype. The guide pairs an emerging astrocyte OGD/R application with established cancer-model observations, while highlighting controls needed to interpret a dual, high-micromolar inhibitor.
-
Belinostat (PXD101): In Vitro Assay Workflow
2026-09-26
Use Belinostat (PXD101) to probe how pan-HDAC inhibition changes histone acetylation, proliferation, cell-cycle distribution, and cell killing in cancer models. A paired-readout workflow helps distinguish growth arrest from loss of viable cells—two drug responses that a single endpoint can blur.
-
BCL-2 Targeting Across Heterogeneous CRPC
2026-09-25
Single-cell imaging and preclinical models show that BCL-2-positive prostate cancer cells increase in castration-resistant disease, including cells with different androgen-receptor states. The study links AR inhibition to BCL-2 derepression and provides early clinical evidence that combining enzalutamide with venetoclax may reduce circulating tumor cells in some patients.
-
3X (DYKDDDDK) Peptide for Protein Workflows
2026-09-25
Use the 3X (DYKDDDDK) Peptide as a soluble competitor to help release FLAG-tagged proteins from affinity matrices and support clean downstream analysis. This workflow-focused guide connects tag-based protein handling to kinase-substrate research while flagging the controls needed for phosphorylation and metal-sensitive assays.
-
ATRX Loss and the Translational Case for RTK Inhibition
2026-09-24
ATRX deficiency may help explain why some high-grade glioma cells respond differently to receptor tyrosine kinase and PDGFR inhibitors. This article examines the mechanistic rationale, experimental considerations, and clinical-trial implications—and offers a cautious framework for evaluating AZ 10417808 without assuming an unverified target or study role.
-
Cecal Omics After E. tenella Treatment in Chickens
2026-09-24
This study paired 16S rRNA gene sequencing with LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment reshape the chicken cecal environment. Ethanamizuril was associated with a microbiota profile interpreted as more stable, while sulfachlorpyridazine was associated with lower Escherichia-Shigella; the low-dose combination had limited effects under the conditions tested.
-
DCFH-DA Workflows for Cellular ROS Assays
2026-09-23
Use DCFH-DA to compare intracellular oxidative activity across microscopy, flow cytometry, and plate-reader workflows—not to identify a specific ROS or its source. A granulosa-cell study of LSKL and THBS1 offers a practical disease-model example, with controls and optimization tips for making fluorescence results more interpretable.
-
M344: From Chromatin Control to Cancer Assays
2026-09-23
M344 is a cell-permeable histone deacetylase inhibitor that links chromatin remodeling to cell-cycle arrest, apoptosis, differentiation, and tumor control. This evidence-driven guide explains how to select assays, interpret exposure, and translate neuroblastoma findings into rigorous cancer research workflows.
-
Dual HER2–VEGFR-2 Targeting in Breast Cancer
2026-09-22
A 2026 study examined Lapatinib and Telatinib in HER2-negative MDA-MB-231 triple-negative breast cancer cells, showing reduced proliferation, invadopodia formation, and two-dimensional tube formation. The work supports phenotype-first targeted cancer therapy research while leaving direct receptor engagement and formal combination synergy unresolved.
-
PFHxS Hepatotoxicity via PPAR Signaling in Zebrafish
2026-09-22
The reference study shows that environmentally relevant exposure to perfluorohexanesulfonic acid (PFHxS) can damage developing zebrafish liver through a PPAR-associated mechanism. Its main advance is the combination of transcriptomics, pathology, biochemical measurements, targeted gene analysis, pharmacological antagonism, and PPAR morpholino knockdown to connect pathway enrichment with observable hepatotoxicity.
-
SIRT1/2 Inhibitor IV: A Mechanism-First Guide
2026-09-21
SIRT1/2 Inhibitor IV (cambinol) provides a cell-permeable way to interrogate SIRT1/2-dependent acetylation, metabolism, and tumor biology. This guide connects biochemical validation with lactylation, astrocyte, p53, and xenograft assay decisions while clearly separating evidence from testable hypotheses.
-
SIRT1, Type H Vessels, and Aging Bone Repair
2026-09-21
Liu et al. show that SIRT1 coordinates endothelial activity and osteogenic differentiation in aged bone models, with β-catenin deacetylation and nuclear translocation implicated as a mechanistic link to Wnt signaling. The study connects vascular–skeletal dysfunction with impaired regeneration and supports SIRT1 activation as a research strategy for age-related bone repair, while leaving important translational questions unresolved.
-
Tubastatin A Protects the Heart After Cardiac Arrest
2026-09-20
A 2025 porcine study reports that Tubastatin A reduced myocardial dysfunction and injury after cardiac arrest and resuscitation, with effects associated with lower GSDME-related pyroptosis and MLKL-related necroptosis. The findings extend HDAC6 inhibitor research into a clinically relevant large-animal model while emphasizing that pathway involvement, rather than definitive causality, remains to be established.
-
GlycoRNA–RBP Domains Shape Cell-Surface Entry
2026-09-19
The reference preprint proposes that cell-surface RNA-binding proteins and glycoRNAs assemble into organized nanoclusters rather than existing as isolated surface components. Perturbation experiments connect these domains to TAT cell-penetrating peptide entry, expanding the functional definition of the plasma membrane and suggesting new strategies for studying extracellular molecular organization.
-
Nullscript: A Practical HDAC Inhibitor Workflow
2026-09-18
Nullscript is a histone deacetylase inhibitor designed for experiments that separate HDAC-dependent chromatin effects from transcriptional reporter activation. Its reporter-inactive profile and preclinical cardiac ischemia/reperfusion signal make it useful for orthogonal assay design, mechanism testing, and translational model development.